# EDGAR Filing Document

**Accession Number:** 0001626199
**File Stem:** 0001172661-23-001379
**Filing Date:** 2023-2
**Character Count:** 24440
**Document Hash:** 91945f56e958e80282ea55fb4579b7b8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001172661-23-001379.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001172661-23-001379

**CONFORMED SUBMISSION TYPE**: SC 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALPINE IMMUNE SCIENCES, INC.
- **CENTRAL INDEX KEY:** 0001626199
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 208969493
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-88896
- **FILM NUMBER:** 23631061

**BUSINESS ADDRESS:**
- **STREET 1:** 188 EAST BLAINE ST., SUITE 200
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98102
- **BUSINESS PHONE:** 206-788-4545

**MAIL ADDRESS:**
- **STREET 1:** 188 EAST BLAINE ST., SUITE 200
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Nivalis Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20150211

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** N30 Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20141121
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GREAT POINT PARTNERS LLC
- **CENTRAL INDEX KEY:** 0001281446
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** 165 MASON STREET, 3RD FLOOR
- **CITY:** GREENWICH
- **STATE:** CT
- **ZIP:** 06830
- **BUSINESS PHONE:** 203 971-3300

**MAIL ADDRESS:**
- **STREET 1:** 165 MASON STREET, 3RD FLOOR
- **CITY:** GREENWICH
- **STATE:** CT
- **ZIP:** 06830

------

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION<br> Washington, DC 20549**

**SCHEDULE 13G/A**

**Under the Securities Exchange Act of 1934**

**(Amendment No. 1)\***

**ALPINE IMMUNE SCIENCES, INC.**

---

| |
|:---|
| &nbsp;&nbsp;(Name of Issuer) |
| &nbsp;&nbsp; <br> **Common Stock, par value $0.001 per share**<br>|
| &nbsp;&nbsp;(Title of Class of Securities) |
| &nbsp;&nbsp;<br> **02083G100**<br>|
| &nbsp;&nbsp;(CUSIP Number) |
| &nbsp;&nbsp; **December 31, 2022** |
| &nbsp;&nbsp;(Date of Event Which Requires Filing of this Statement) |

---

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

□ Rule 13d-1(b)

⌧ Rule 13d-1(c)

□ Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

------

---

| | | |
|:---|:---|:---|
| **CUSIP No. 02083G100** | **SCHEDULE 13G/A** | &nbsp;&nbsp;&nbsp; **Page 2 of 9 Pages** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| 1 | NAME OF REPORTING PERSONS<br>Great Point Partners, LLC | NAME OF REPORTING PERSONS<br>Great Point Partners, LLC | NAME OF REPORTING PERSONS<br>Great Point Partners, LLC | NAME OF REPORTING PERSONS<br>Great Point Partners, LLC |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP <br> (a) □<br> (b) □ | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP <br> (a) □<br> (b) □ | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP <br> (a) □<br> (b) □ |  |
| 3 | SEC USE ONLY | SEC USE ONLY | SEC USE ONLY | SEC USE ONLY |
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION<br>Delaware | CITIZENSHIP OR PLACE OF ORGANIZATION<br>Delaware | CITIZENSHIP OR PLACE OF ORGANIZATION<br>Delaware | CITIZENSHIP OR PLACE OF ORGANIZATION<br>Delaware |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 5 | SOLE VOTING POWER<br>0 | SOLE VOTING POWER<br>0 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 6 | SHARED VOTING POWER<br>3,637,718 | SHARED VOTING POWER<br>3,637,718 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 7 | SOLE DISPOSITIVE POWER<br>0 | SOLE DISPOSITIVE POWER<br>0 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 8 | SHARED DISPOSITIVE POWER<br>3,637,718 | SHARED DISPOSITIVE POWER<br>3,637,718 |
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>3,637,718 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>3,637,718 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>3,637,718 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>3,637,718 |
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  | o |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>7.92%<sup>1</sup> | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>7.92%<sup>1</sup> | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>7.92%<sup>1</sup> | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>7.92%<sup>1</sup> |
| 12 | TYPE OF REPORTING PERSON <br>IA/OO | TYPE OF REPORTING PERSON <br>IA/OO | TYPE OF REPORTING PERSON <br>IA/OO | TYPE OF REPORTING PERSON <br>IA/OO |

---

<sup>1</sup> Based on a total of 45,914,433 shares of common stock outstanding as reported by the Issuer in its Form 10-Q filed with the SEC on November 14, 2022.

------

---

| | | |
|:---|:---|:---|
| **CUSIP No. 02083G100** | **SCHEDULE 13G/A** | &nbsp;&nbsp;&nbsp; **Page 3 of 9 Pages** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| 1 | NAME OF REPORTING PERSONS<br>Dr. Jeffrey R. Jay, M.D. | NAME OF REPORTING PERSONS<br>Dr. Jeffrey R. Jay, M.D. | NAME OF REPORTING PERSONS<br>Dr. Jeffrey R. Jay, M.D. | NAME OF REPORTING PERSONS<br>Dr. Jeffrey R. Jay, M.D. |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP <br> (a) □<br> (b) □ | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP <br> (a) □<br> (b) □ | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP <br> (a) □<br> (b) □ |  |
| 3 | SEC USE ONLY | SEC USE ONLY | SEC USE ONLY | SEC USE ONLY |
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION<br>USA | CITIZENSHIP OR PLACE OF ORGANIZATION<br>USA | CITIZENSHIP OR PLACE OF ORGANIZATION<br>USA | CITIZENSHIP OR PLACE OF ORGANIZATION<br>USA |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 5 | SOLE VOTING POWER<br>0 | SOLE VOTING POWER<br>0 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 6 | SHARED VOTING POWER<br>3,637,718 | SHARED VOTING POWER<br>3,637,718 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 7 | SOLE DISPOSITIVE POWER<br>0 | SOLE DISPOSITIVE POWER<br>0 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 8 | SHARED DISPOSITIVE POWER<br>3,637,718 | SHARED DISPOSITIVE POWER<br>3,637,718 |
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>3,637,718 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>3,637,718 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>3,637,718 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>3,637,718 |
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  | o |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>7.92%<sup>1 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>7.92%<sup>1 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>7.92%<sup>1 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>7.92%<sup>1 |
| 12 | TYPE OF REPORTING PERSON <br>IN/HC | TYPE OF REPORTING PERSON <br>IN/HC | TYPE OF REPORTING PERSON <br>IN/HC | TYPE OF REPORTING PERSON <br>IN/HC |

---

<sup>1</sup> Based on a total of 45,914,433 shares of common stock outstanding as reported by the Issuer in its Form 10-Q filed with the SEC on November 14, 2022.

------

---

| | | |
|:---|:---|:---|
| **CUSIP No. 02083G100** | **SCHEDULE 13G/A** | &nbsp;&nbsp;&nbsp; **Page 4 of 9 Pages** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| 1 | NAME OF REPORTING PERSONS<br>Mr. Ortav Yehudai | NAME OF REPORTING PERSONS<br>Mr. Ortav Yehudai | NAME OF REPORTING PERSONS<br>Mr. Ortav Yehudai | NAME OF REPORTING PERSONS<br>Mr. Ortav Yehudai |
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP <br> (a) □<br> (b) □ | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP <br> (a) □<br> (b) □ | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP <br> (a) □<br> (b) □ |  |
| 3 | SEC USE ONLY | SEC USE ONLY | SEC USE ONLY | SEC USE ONLY |
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION<br>USA | CITIZENSHIP OR PLACE OF ORGANIZATION<br>USA | CITIZENSHIP OR PLACE OF ORGANIZATION<br>USA | CITIZENSHIP OR PLACE OF ORGANIZATION<br>USA |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 5 | SOLE VOTING POWER<br>0 | SOLE VOTING POWER<br>0 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 6 | SHARED VOTING POWER<br>3,637,718 | SHARED VOTING POWER<br>3,637,718 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 7 | SOLE DISPOSITIVE POWER<br>0 | SOLE DISPOSITIVE POWER<br>0 |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 8 | SHARED DISPOSITIVE POWER<br>3,637,718 | SHARED DISPOSITIVE POWER<br>3,637,718 |
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>3,637,718 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>3,637,718 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>3,637,718 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>3,637,718 |
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  | o |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>7.92%<sup>1 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>7.92%<sup>1 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>7.92%<sup>1 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)<br>7.92%<sup>1 |
| 12 | TYPE OF REPORTING PERSON <br>IN/HC | TYPE OF REPORTING PERSON <br>IN/HC | TYPE OF REPORTING PERSON <br>IN/HC | TYPE OF REPORTING PERSON <br>IN/HC |

---

<sup>1</sup> Based on a total of 45,914,433 shares of common stock outstanding as reported by the Issuer in its Form 10-Q filed with the SEC on November 14, 2022.

------

---

| | | |
|:---|:---|:---|
| **CUSIP No. 02083G100** | **SCHEDULE 13G/A** | &nbsp;&nbsp;&nbsp; **Page 5 of 9 Pages** |

---

**Item 1.** **(a) Name of Issuer**

ALPINE IMMUNE SCIENCES, INC.

**Item 1.** **(b) Address of Issuer's Principal Executive Offices**

188 East Blaine Street, Suite 200

Seattle, Washington 98102

**Item 2.** **(a) Names of Persons Filing:**

Great Point Partners, LLC

Dr. Jeffrey R. Jay, M.D.

Mr. Ortav Yehudai

The Reporting Persons have entered into a Joint Filing Agreement, dated February 14, 2023, a copy of which is filed with this SCHEDULE 13G/A as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.

**Item 2.** **(b) Address of Principal Business Office:**

The address of the principal business office of each of the Reporting Persons is

165 Mason Street, 3rd Floor

Greenwich, CT 06830

**Item 2.** **(c) Citizenship:**

Great Point Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States. Mr. Ortav Yehudai is a citizen of the United States.

**Item 2.** **(d) Title of Class of Securities**

Common Stock, par value $0.001 per share (the "common stock")

**Item 2.** **(e) CUSIP No.:** 

02083G100

---

| | | |
|:---|:---|:---|
| **CUSIP No. 02083G100** | **SCHEDULE 13G/A** | &nbsp;&nbsp;&nbsp; **Page 6 of 9 Pages** |

---

(a) ◻ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b) ◻ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) ◻ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d) ◻ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e) □ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f) ◻ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g) ◻ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h) ◻ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) ◻ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the
 Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) ◻ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

(k) ◻ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J),
 please specify the type of institution: <u> </u> 

---

| | | |
|:---|:---|:---|
| **CUSIP No. 02083G100** | **SCHEDULE 13G/A** | &nbsp;&nbsp;&nbsp; **Page 7 of 9 Pages** |

---

**Item 4. Ownership**

Biomedical Value Fund, L.P. ("BVF") is the record owner of 2,073,499 shares (the "BVF Shares"). Great Point Partners, LLC ("Great Point") is the investment manager of BVF, and by virtue of such status may be deemed to be the beneficial owner of the BVF Shares. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as Senior Managing Member of Great Point, and Mr. Ortav Yehudai ("Mr. Yehudai"), as Managing Director of Great Point, has voting and investment power with respect to the BVF Shares, and therefore may be deemed to be the beneficial owner of the BVF Shares.

Biomedical Offshore Value Fund, Ltd. ("BOVF") is the record owner of 1,382,333 shares (the "BOVF Shares"). Great Point is the investment manager of BOVF, and by virtue of such status may be deemed to be the beneficial owner of the BOVF Shares. Each of Dr. Jay, as Senior Managing Member of Great Point, and Mr. Yehudai, as Managing Director of Great Point, has voting and investment power with respect to the BOVF Shares, and therefore may be deemed to be the beneficial owner of the BOVF Shares.

Cheyne Global Equity Fund (an Open-Ended Fund of Cheyne Select Master Fund ICAV) ("CGEF") is the record holder of 181,886 shares of Common Stock (the "CGEF Shares"). Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as senior managing member of Great Point, and Mr. Ortav Yehudai ("Mr. Yehudai"), as Managing Director of Great Point, has voting and investment power with respect to the CGEF Shares, and therefore may be deemed to be the beneficial owner of the CGEF Shares.

Notwithstanding the above, Great Point, Dr. Jay and Mr. Yehudai disclaim beneficial ownership of the BVF Shares, the BOVF Shares, and the CGEF Shares, except to the extent of their respective pecuniary interests.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. **Great Point Partners, LLC**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Amount beneficially owned: 3,637,718

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Percent of class: 7.92%<sup>1</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Number of shares as to which the person has:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Sole power to vote or direct the vote: 0

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Shared power to vote or direct the vote: 3,637,718

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Sole power to dispose or to direct the disposition of: 0

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Shared power to dispose or to direct the disposition of: 3,637,718

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. **Dr. Jeffrey R. Jay, M.D.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Amount beneficially owned: 3,637,718

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Percent of class: 7.92%<sup>1</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Number of shares as to which the person has:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Sole power to vote or direct the vote: 0

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Shared power to vote or direct the vote: 3,637,718

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Sole power to dispose or to direct the disposition of: 0

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Shared power to dispose or to direct the disposition of: 3,637,718

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. **Mr. Ortav Yehudai**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Amount beneficially owned: 3,637,718

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Percent of class: 7.92%<sup>1</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Number of shares as to which the person has:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Sole power to vote or direct the vote: 0

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Shared power to vote or direct the vote: 3,637,718

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Sole power to dispose or to direct the disposition of: 0

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Shared power to dispose or to direct the disposition of: 3,637,718

<sup>1</sup></sup>Based on a total of 45,914,433 shares of common stock outstanding as reported by the Issuer in its Form 10-Q filed with the SEC on November 14, 2022.

**Item 5. Ownership of Five Percent or Less of a Class**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

**Item 6. Ownership of More Than Five Percent on Behalf of Another Person**

See Item 4.

**Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person**

Not Applicable.

**Item 8. Identification and Classification of Members of the Group**

Not Applicable.

**Item 9. Notice of Dissolution of Group**

Not Applicable.

**Item 10. Certification**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

---

| | | |
|:---|:---|:---|
| **CUSIP No. 02083G100** | **SCHEDULE 13G/A** | &nbsp;&nbsp;&nbsp; **Page 8 of 9 Pages** |

---

**<u>SIGNATURE</u>**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2023

---

| | |
|:---|:---|
| **Great Point Partners, LLC** | **Great Point Partners, LLC** |
| By: | /s/ Dr. Jeffrey R. Jay, M.D. |
|  | Dr. Jeffrey R. Jay, M.D., as Senior Managing Member |

---

---

| | |
|:---|:---|
| **Dr. Jeffrey R. Jay, M.D.** | **Dr. Jeffrey R. Jay, M.D.** |
| By: | /s/ Dr. Jeffrey R. Jay, M.D. |
|  | Dr. Jeffrey R. Jay, M.D. |

---

---

| | |
|:---|:---|
| **Mr. Ortav Yehudai** | **Mr. Ortav Yehudai** |
| By: | /s/ Mr. Ortav Yehudai |
|  | Mr. Ortav Yehudai |

---

---

| | | |
|:---|:---|:---|
| **CUSIP No. 02083G100** | **SCHEDULE 13G/A** | &nbsp;&nbsp;&nbsp; **Page 9 of 9 Pages** |

---

<u>Exhibit A</u>

**JOINT FILING STATEMENT**

**PURSUANT TO RULE 13d-1(k)**

The undersigned hereby agree as follows:

(i) Each of them is individually eligible to use the SCHEDULE 13G/A to which this Exhibit is attached, and such SCHEDULE 13G/A is filed on behalf of each of them; and

(ii) Each of them is responsible for the timely filing of such SCHEDULE 13G/A and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

Dated: February 14, 2023

---

| | |
|:---|:---|
| **Great Point Partners, LLC** | **Great Point Partners, LLC** |
| By: | /s/ Dr. Jeffrey R. Jay, M.D. |
|  | Dr. Jeffrey R. Jay, M.D., as Senior Managing Member |

---

---

| | |
|:---|:---|
| **Dr. Jeffrey R. Jay, M.D.** | **Dr. Jeffrey R. Jay, M.D.** |
| By: | /s/ Dr. Jeffrey R. Jay, M.D. |
|  | Dr. Jeffrey R. Jay, M.D. |

---

---

| | |
|:---|:---|
| **Mr. Ortav Yehudai** | **Mr. Ortav Yehudai** |
| By: | /s/ Mr. Ortav Yehudai |
|  | Mr. Ortav Yehudai |

---